ECSP19043725A - Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares - Google Patents

Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares

Info

Publication number
ECSP19043725A
ECSP19043725A ECSENADI201943725A ECDI201943725A ECSP19043725A EC SP19043725 A ECSP19043725 A EC SP19043725A EC SENADI201943725 A ECSENADI201943725 A EC SENADI201943725A EC DI201943725 A ECDI201943725 A EC DI201943725A EC SP19043725 A ECSP19043725 A EC SP19043725A
Authority
EC
Ecuador
Prior art keywords
amino acid
methods
disorders
treatment
acid compositions
Prior art date
Application number
ECSENADI201943725A
Other languages
English (en)
Inventor
William Comb
Michael Hamill
Raffi Afeyan
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of ECSP19043725A publication Critical patent/ECSP19043725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción proporciona composiciones que comprenden entidades de aminoácidos. La descripción también proporciona métodos para mejorar función muscular que comprende la administración de una cantidad eficaz de las composiciones a un sujeto que lo necesita.
ECSENADI201943725A 2016-12-19 2019-06-19 Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares ECSP19043725A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US201762491776P 2017-04-28 2017-04-28
US201762545358P 2017-08-14 2017-08-14
US201762576321P 2017-10-24 2017-10-24

Publications (1)

Publication Number Publication Date
ECSP19043725A true ECSP19043725A (es) 2019-07-31

Family

ID=61025047

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201943725A ECSP19043725A (es) 2016-12-19 2019-06-19 Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares

Country Status (21)

Country Link
US (3) US20180207119A1 (es)
EP (1) EP3554493A1 (es)
JP (1) JP2020502183A (es)
KR (1) KR20190099243A (es)
CN (1) CN110267655A (es)
AU (1) AU2017379825A1 (es)
BR (1) BR112019012476A2 (es)
CA (1) CA3046558A1 (es)
CL (1) CL2019001685A1 (es)
CO (1) CO2019006292A2 (es)
CU (1) CU20190057A7 (es)
EC (1) ECSP19043725A (es)
IL (1) IL267210A (es)
JO (1) JOP20190147A1 (es)
MA (1) MA50763A (es)
MX (1) MX2019007352A (es)
PE (1) PE20191206A1 (es)
PH (1) PH12019501339A1 (es)
TW (1) TWI780096B (es)
WO (1) WO2018118957A1 (es)
ZA (1) ZA201903581B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
EP3684350A1 (en) * 2017-08-14 2020-07-29 Axcella Health Inc. Amino acids compositions for the treatment of neuronal injury
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
JP2021527670A (ja) * 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
EP3810168A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Methods of manufacturing amino acid compositions
JP2021529736A (ja) * 2018-06-20 2021-11-04 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 炎症の軽減又は治療のための組成物及び方法
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
JP2022501321A (ja) * 2018-09-27 2022-01-06 ソシエテ・デ・プロデュイ・ネスレ・エス・アー インスリン抵抗性及び／又は糖尿病の予防のための、ヒスチジンとグリシンと他のアミノ酸の使用
EP3980002A1 (en) * 2019-06-07 2022-04-13 Société des Produits Nestlé S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
IT201900010437A1 (it) 2019-06-28 2020-12-28 Dompe Farm Spa Composizione per il trattamento del deperimento muscolare
KR102456270B1 (ko) * 2019-09-24 2022-10-19 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
KR102338447B1 (ko) * 2019-09-24 2021-12-14 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
CN110801007A (zh) * 2019-12-17 2020-02-18 苟春虎 老年肌少症营养肽
US20230089723A1 (en) * 2020-03-06 2023-03-23 Axcella Health Inc. Amino acid compositions and methods for muscle and myotube modulation
WO2022181936A1 (ko) * 2021-02-26 2022-09-01 이엑스헬스케어 주식회사 피부 유래 엑소좀을 통해 근손실 억제 또는 근생성 촉진 효과를 나타내는 조성물
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399500A1 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement for increasing lean muscle mass and strength
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
WO2006105112A2 (en) * 2005-03-29 2006-10-05 Ajinomoto Co., Inc. Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
CN100518815C (zh) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
EP2744356A4 (en) * 2011-08-19 2015-05-27 Musclepharm Corp COMPOSITIONS AND METHODS FOR INHIBITING INCOUNTERANCE IN ANIMALS
JP2017501113A (ja) * 2013-10-23 2017-01-12 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ アミノ酸によるｍＴＯＲＣ１の調節およびその使用

Also Published As

Publication number Publication date
JP2020502183A (ja) 2020-01-23
MX2019007352A (es) 2019-09-05
KR20190099243A (ko) 2019-08-26
US20180169046A1 (en) 2018-06-21
CN110267655A (zh) 2019-09-20
TWI780096B (zh) 2022-10-11
IL267210A (en) 2019-08-29
AU2017379825A1 (en) 2019-06-13
US20180207119A1 (en) 2018-07-26
CA3046558A1 (en) 2018-06-28
PH12019501339A1 (en) 2019-09-30
BR112019012476A2 (pt) 2020-04-14
TW201827068A (zh) 2018-08-01
WO2018118957A1 (en) 2018-06-28
PE20191206A1 (es) 2019-09-10
CU20190057A7 (es) 2020-02-04
JOP20190147A1 (ar) 2019-06-18
CL2019001685A1 (es) 2019-08-30
CO2019006292A2 (es) 2019-06-28
US20180169047A1 (en) 2018-06-21
MA50763A (fr) 2019-10-23
ZA201903581B (en) 2020-12-23
EP3554493A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
ECSP20011578A (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
EA201790398A1 (ru) Способы лечения заболевания печени
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
AR115585A1 (es) Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2020004397A (es) Uso de suplementos de aminoacidos para mejorar la sintesis de proteinas musculares.
EA201791154A1 (ru) Лечение болезней и нарушений аналогами кальцитонина
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2019000849A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
EA201991504A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний и нарушений мышц
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
EA201991502A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний печени
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso